Dallas, TX 12/12/2007 11:46:43 AM
OTCPicks.com Stocks to Watch for Wednesday, December 12th AWYI, SLNH, AMZO, AVXT, VGWA, PRPM
Our Stocks to Watch tomorrow include Ariel Way, Inc. (OTCBB: AWYI), Splinternet Holdings, Inc. (OTCBB: SLNH), Amazon Biotech, Inc. (OTCBB: AMZO), AVAX Technologies, Inc. (OTCBB: AVXT), visionGATEWAY Inc. (OTC: VGWA) and Propalms, Inc. (OTC: PRPM).
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts
ARIEL WAY INCORPORATED (OTCBB: AWYI)
"Up 62.50% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/AWYI.php
Ariel Way, Inc. operates as a technology and services company for global communications, multimedia, and digital signage solutions and technologies. It develops and deploys solutions for business television, digital signage, and interactive media delivered over a combination of satellite, terrestrial, and wireless local networks. The company's digital signage service includes technologies using LCD television and plasma screens to deliver video based messaging directly to consumer audiences. Its integrated multimedia services include music radio, video, and Internet protocol based file transfer for training/catalogs/point of sale integrated with other information to the clients. Ariel Way serves finance-oriented services companies primarily in United Kingdom. The company is headquartered in Vienna, Virginia.
AWYI News:
December 11 - Ariel Way, Inc. Signs LOI to Acquire Syrei Holding UK, Ltd
Deal Expected to Add More than $7.5 Million Revenue, be Immediately Accretive to Ariel Way 2008 Earnings
Ariel Way, Inc. (OTCBB: AWYI) announced that the Company has signed a letter of intent to acquire Syrei Holding UK, Ltd, a UK and Sweden based a telecom-consulting firm comprised of senior specialists and experts in the evolving global telecommunications market (http://www.syrei.com/). The deal is forecast to add more than $7.5 million in annualized revenue and to be accretive to Ariel Way's 2008 earnings with over 10% EBITDA. The transaction, which is subject to the signing of definitive agreements and customary closing conditions, has a two-step closing process with a first expected closing in late December 2007. The terms of the transaction were not disclosed.
Arne Dunhem, Ariel Way president and CEO, said, "We are excited with the prospect of having Syrei and its highly skilled consultants to be part of our operation. Thomas Strangert's team of technical experts have over ten years successfully provided and will continue to provide services worldwide to major corporations and telecom operators. They will also add global expertise to our strategy of building a state-of-the-art highly secure Digital Signage Network and will have primary focus on markets in Europe and Asia. We expect this acquisition to be immediately accretive to Ariel Way's earnings. Further, upon the full integration of this transaction, we anticipate moving into the black at the operating income line on a consolidated basis."
Thomas Strangert, CEO of Syrei, said, "We are looking forward to working with Arne and his team to integrate Syrei with Ariel Way's strategy. We are excited about actively supporting the Digital Signage activities in Europe and Asia in addition to continue to expand our current customer base on a worldwide basis."
Syrei, founded in 1997, is a telecom-consulting firm operating out of the UK and Sweden comprised of senior specialists and experts in the evolving global telecommunications market. Syrei's management and technical experts have successfully delivered professional services to value added service providers, telecom equipment manufactures and operators in more than 40 countries around the world. Syrei is a complete solution provider and a system integrator that is able to accept the total responsibility of large and complex projects. Syrei's consultants have been brought in to advise and aid major corporations and telecom operators like Ericsson, Nokia, 3GIS, ABB, Orange, SonyEricsson, Swedbank, Tele2, TeliaSonera, TIM etc.
SPLINTERNET HOLDINGS (OTCBB: SLNH)
"Up 36.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/SLNH.php
Splinternet Holdings, Inc., through its wholly owned subsidiary, Splinternet Communications, Inc., operates as a developer of voice over Internet protocol (VoIP) technology and services, which enable customers to make phone calls utilizing the Internet as an alternative to the traditional public switched telephone network (PSTN). The company's solutions overlays voice communications on top of customers' high-speed Internet connection. It also resells excess VoIP capacity primarily to traditional international long distance carriers. Splinternet Holdings, Inc. has operations primarily in the United States. The company was founded in 2000 and is based in Norwalk, Connecticut.
SLNH News:
December 11 - Splinternet Holdings Announces Entry into Anti-Terrorism Market
Splinternet Holdings, Inc. (OTCBB: SLNH) announced that it is entering the anti-terrorism market with a new radiation detection device and monitoring system which will provide early warning of the presence of radioactive materials of the type feared to be usable in dirty bombs.
Together with its development of a networked radiation detection device, Splinternet has entered into a cross-licensing and selling agreement with privately-held Vidiation, LLC, a development-stage company with a revolutionary technology to identify radioactive materials by analyzing streams of data from video surveillance systems. Vidiation launched its Vidiation-Radiation Analytics Detection System or V-RADS™ at the Fall 2007 ASIS conference, and plans to enter the market shortly (http://www.vidiation.com/).
Vidiation is the developer of a software-based technology that detects the presence of radiation when it comes in range of a video surveillance camera. The gamma rays from threats such as “dirty bombs” strike an image sensor in the camera causing a detectable pattern of interference. As the data from the camera is examined by Vidiation’s V-RADS software, this radiation pattern is detected and an ALERT is sent to the designated monitoring station. This is strictly a software solution, which doesn’t require modification to the cameras.
The Splinternet device is more sensitive than the software/video camera solution, but it does not provide a video image of the monitored site, as the Vidiation system does. The two systems are wholly compatible and complementary.
Vidiation’s software solution dovetails with Splinternet’s existing VoIP infrastructure, and requires no additional commitment of capital or retrofitting of Splinternet’s existing network. By leveraging its VoIP expertise, Splinternet has developed a small hardware-based radiation detection device to work in conjunction with Vidiation’s software by functioning as a smart networked radiation detection node. Like Splinternet’s VoIP solution, the combined Splinternet/Vidiation products will network using Ethernet technology and will be managed via a local LAN or the World Wide Web.
Splinternet's President, James Ackerly said, “Splinternet and Vidiation have each developed ways to monitor large areas for the existence of gamma ray-emitting substances, and the realization that our two techniques are helpful to each other, rather than competitive has led us to the new business arrangement we are announcing today. We are pleased to enter the 'War on Terrorism’ in this way, as the availability of wide area detection systems will serve as a deterrent to those who would hope to sneak a dirty bomb into an economically or politically strategic location. We have been attracted to the anti-terrorism space for some time and believe that with Vidiation we have a compelling entry into the market. We believe there is significant demand worldwide for this service, which offers customers a new layer of protection from improper transport of high energy materials.”
Ackerly continued, “We have tested the prototype combined system in real-world medical facilities and are pleased with the results. We will work with Vidiation toward achieving government validation, which we expect will be realized in early 2Q08, at which time we plan to begin aggressively selling the systems. In fact, the US Government has budgeted over $1 billion in 2007 for radiation detection systems, but it is reported that they are dissatisfied with the existing solutions. We believe our combined offering will have a significant impact in the radiation detection market. We are excited about this new product offering and plan to continue our strategy of targeting partnerships and acquisitions with innovative product offerings that can leverage our management and our network expertise.”
AMAZON BIOTECH INCORPORATED (OTCBB: AMZO)
"Up 40.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/AMZO.php
Amazon Biotech, Inc., a development stage company, engages in the research and development of natural drugs in the United States. It owns rights to an investigational drug candidate, AMZ0026, which is a naturally derived pharmaceutical drug compound made up of plant substances for the treatment of HIV/AIDS. The company also develops AMZ0026-H, which is a whole-plant pharmaceutical drug under development for the treatment of AIDS symptoms. In addition, it owns rights to a natural hair growth product known as AMZHG001, which contains proprietary herbal ingredients. Amazon Biotech is based in New York, New York.
AMZO News:
December 10 - Amazon Biotech, Inc. Issues Shareholder Update of Corporate Developments
Company to Initiate Phase I/II Clinical Trials for AIDS Drug AMZ0026
Amazon Biotech, Inc. (OTCBB: AMZO) (Frankfurt: B2D.F) has released the following update to shareholders:
In the past six months, Amazon Biotech, Inc. has raised $215,000 in capital and is in negotiations for a further $2.3 Million. Upon the successful completion of funding the Company will focus on initiating phase I/II trials for its AIDS Drug AMZ0026.
The approved trial protocol is designed to test the safety, immunological and antiviral effects of AMZ0026, Amazon Biotech's anti-HIV parent formula. The double blind, placebo-controlled clinical trial design involves 32 non-symptomatic HIV subjects who have yet to be treated with Highly Active Anti-Retroviral Therapy (HAART). The six-month study will include the monitoring of T-Cell increases and HIV plasma viral load decreases.
The company is also in early discussions with pharmaceutical companies about possible joint ventures.
Dr. Mechael Kanovsky, CEO of Amazon Biotech, said: "We believe that we have a potential efficacious and safe treatment for HIV/AIDS. We are diligently working on obtaining the funding for this important drug trial. The capital has taken longer to raise than initially anticipated but we will continue to focus on closing on the necessary financing for both the humanitarian and commercial aspects of our drug."
AVAX TECHNOLOGIES (OTCBB: AVXT)
"Up 36.36% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/AVXT.php
AVAX Technologies, Inc., a biopharmaceutical company, engages in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company primarily focuses on the development of an autologous cell vaccine, referred to as M-Vax, which is in Phase I/II clinical trial for the postsurgical treatment of late stage melanoma. AVAX Technologies also develops L-Vax, a Phase I/II clinical trial product for the treatment of non-small cell lung cancer; and O-Vax, a Phase I/II clinical trial product for ovarian cancer. It also offers contract-manufacturing services for biological products to other pharmaceutical and biotechnology companies. The company was founded in 1990 and is based in Philadelphia, Pennsylvania.
AVXT News:
December 10 - AVAX Technologies Announces Successful Completion of Phase I / II Study of MVax(R) in Patients with Stage 3 and 4 Melanoma
AVAX Technologies, Inc. (OTCBB: AVXT) announced the completion of its Phase I/II study for the treatment of patients with melanoma. The study was designed to evaluate four doses of MVax® with dose defined by the number of cells injected in each vaccine; the doses tested were: 5x106 cells (high dose), 2.5x106 cells (medium dose), 0.5x106 cells (low dose), and 0 cells (zero dose). All dosages were administered according to a previously developed optimum schedule, which included an induction dose without adjuvant followed by low dose cyclophosphamide and then 6 doses admixed with the immunological adjuvant, BCG, Endpoints of the study were safety and an immunological endpoint of delayed-type hypersensitivity (DTH), which is a T-cell-mediated immune response to autologous melanoma cells. The study was also designed to demonstrate that the frozen formulation of MVax® is bio-equivalent to the original, freshly-prepared autologous, hapten-modified vaccine.
The high dose arm of vaccine was highly effective immunologically with positive DTH responses to hapten-modified autologous melanoma cells observed in 22/29 (76%) patients following a course of MVax®; baseline DTH responses were negative, as a condition of enrollment. In contrast, the zero dose arm was ineffective. Linear regression analysis of DTH responses of all evaluable patients showed a clear dose-response relationship when DTH responses for each patient were plotted against the MVax® dose received. These results are important, because previously published studies by AVAX and others showed a statistically significant relationship was seen between survival and induction of DTH after MVax® administration.
The safety profile of MVax® appeared to be very favorable. There were no Serious Adverse Events attributed to MVax®. Non-serious adverse events were similar to what has been observed in previous trials of the autologous, haptenized vaccine: mild-moderate injection site reactions in all patients, mild nausea from cyclophosphamide in some patients, and mild constitutional symptoms, such as fatigue, in some patients after MVax® administration.
“We believe this is the first demonstration of a dose response relationship using a cellular based cancer vaccine, and the data extend our earlier published work in exploring the immunopharmacology of MVax®,” stated Dr. David Berd, Chief Medical Officer of AVAX and Inventor of MVax®. “This study has provided us with additional insight into the complex pharmacology of biologic therapies that we consider to be critical for the future design and development of therapeutics for the treatment of patients. This study also confirms the fact that the re-engineered “frozen” vaccine platform induces immunological effects similar to those induced by the original freshly-prepared vaccine manufacturing platform. Finally, the dose-response data generated by this study enabled us to rationally choose a dosage range for the company’s Phase III registration study of MVax®, which has begun enrollment.“
MVax® Phase III Registration Study
AVAX’s Phase III Registration trial will examine survival and anti-tumor response rate using modified response evaluation criteria in solid tumors (modified RECIST criteria) in Stage IV melanoma patients with soft tissue or lung metastasis. The Phase III registration trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for MVax® and in agreement with the FDA the company will be eligible to file for accelerated approval of MVax® based upon achieving a response rate endpoint. The double blind, randomized trial is expected to enroll up to 387 patients to be accrued over a period of 24 months. Patients will be randomized on a two to one basis to the treatment arm or control arm, respectively. The treatment arm consists of MVax® followed by a regimen of low dose IL-2; the control arm consists of placebo vaccine followed by low dose IL-2. Both treatment and control arms include BCG and low dose cyclophosphamide.
MVax® in Metastatic Melanoma
In a phase 2 clinical study published in the International Journal of Cancer, MVax® induced tumor shrinkage in 11/83 patients with surgically incurable stage IV melanoma. In a subsequent paper published by Dr. Michal Lotem in the British Journal of Cancer (British Journal of Cancer 2004, 90 773-780) patients treated with their DNP modified tumor cells, using manufacturing techniques similar to MVax®, followed by administration of low dose interleukin-2, achieved a response rate of 35%. These results were confirmed in a subsequent study conducted by the same investigator that showed a 32% response rate, including 13% complete responses and 19% partial responses.
MVax® in Stage III Melanoma
MVax® was the subject of a publication in the Journal of Clinical Oncology that discussed 214 Stage III melanoma patients that were treated with a regimen of MVax® post surgery. No patients were lost to follow-up and they were split between Stage IIIb & Stage IIIc melanoma. All patients on study had completed follow-up and the reported five-year survival rate was 45%. This compares to five-year survival published in similar patient populations who underwent surgery alone of 22%. In addition, the data showed a significant correlation between survival and delayed-type hypersensitivity (DTH) responsiveness to patients’ unmodified tumor cells (P<.001). The journal commissioned an editorial on the publication. In a separate study of a similar patient population using a DNP-modified tumor cell vaccine (British Journal of Cancer 2002 May 20; 86(10): 1534-9), Lotem also showed a positive relationship between survival and DTH to melanoma cells.
About Melanoma
Cancer of the skin is the most common of cancers while melanoma accounts for approximately 3% of skin cancer cases. According to the SEER CanQuest Database and the American Cancer Society, in the U.S. for 2007 it is estimated there will be 59,940 new cases of melanoma with an expected number of deaths from melanoma of 8,110. The estimated prevalence of melanoma in the U.S. in 2007 is 396,242 cases.
Further information on the Clinical Study
To obtain further information on the phase III clinical study, please visit http://www.clinicaltrials.gov/ and look up MVax® or use study identifier NCT00477906. Additionally, the study has been assigned eudraCT number 2007-004406-26 by the EMEA. You may also contact Dr. David Berd or Ellen Bloome, RN at AVAX Technologies, Inc., 2000 Hamilton Street, Suite 204, Philadelphia, PA 19130 (215) 241-9760.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. AVAX’s AC Vaccine platform is a therapeutic cancer vaccine. In addition, the Company performs contract-manufacturing services for biological products for other pharmaceutical and biotechnology companies.
VISIONGATEWAY INCORPORATED (OTC: VGWA)
"Up 28.57% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/VGWA.php
VisionGateway, Inc., through its subsidiaries, engages in the development, distribution, and marketing of software products and solutions in Australia, the United States, Europe, and New Zealand. It offers visionGATEWAY NGN platform that includes various software components, such as Internet resource management and control, secure mail and secure data sharing, voice over Internet protocol, and Internet protocol-based e-Business, m-Commerce, and smart card solutions. The company's core software product INTERScepter is an enterprise business solution that enables organizations in understanding, managing, and exploiting Internet usage and valuable resources, including bandwidth, systems, and employee productivity. The INTERScepter solution also enables managers to control, schedule, and utilize Internet resources, while placing responsibility on users to self manage and modify their Internet usage behavior. VisionGateway offers its products primarily to customers in the telcos/ISP's, technology,
higher education, financial services, SMB, home/SOHO, and professional services. The company is based in San Diego, California.
VGWA News:
December 11 - Sales Moving Swiftly for the New INTERScepter(TM) Solution
visionGATEWAY Inc. (OTC: VGWA) announced that direct sales of the breakthrough INTERScepter(TM) Internet Resource Management Solution have begun in earnest. In the month of November, in addition to the major contracts recently announced, the Brisbane, Australia sales team have completed a growing number of Small to Medium Business (SMB) sales and the business outlook is indicative of accelerating growth.
INTERScepter(TM) is a real-time management, reporting and control solution that allows managers to see what their staff are doing on the internet while at work, as it occurs. It gives Managers the ability to eliminate time wasting and poor behavior. Best of all, no technical knowledge is required to setup and run the solution.
INTERScepter(TM) reports direct to every user. It graphically displays to each user their behavior patterns and advises them of their usage of the internet. In turn it provides Managers with matching in-depth reporting. Once INTERScepter(TM) begins reporting, Managers and users have the ability to more effectively manage their acceptable internet usage policy, facilitating an increase in work productivity in a win-win approach that avoids any unwanted "big brother" conflict.
The results speak for themselves: a case study at one institution demonstrated an immediate 25% reduction in non-work related internet activity when users saw their personal usage through INTERScepter(TM), with a follow-on improvement in their productive output.
Typical sales to small to medium businesses in Brisbane, the location of visionGATEWAY's Australian office, where these businesses have seen firsthand the benefits that INTERScepter can bring them, include:
Speak Out -- an innovative non-profit organization that uses the creative industries to create opportunities for people to overcome disadvantage and change their world. At its core, SpeakOut develops and delivers a number of social change programs that empower young people and their communities to address issues of disadvantage.
Map Magazine produces a monthly life style and design magazine distributed throughout Brisbane and Sydney targeting Generation Y readers.
Niche Realty is renowned for its leadership in boutique real estate, specializing in CBD, fringe and large off the plan corporate and residential apartment developments.
Aluminium Boats Australia Pty Ltd -- builds and engineers fast ferries and vessels for commercial and private applications using the highest quality materials and latest construction techniques.
Affair Magazine is Brisbane's premier luxury lifestyle magazine, entertaining and informing the local Brisbane, Gold and Sunshine Coast market as well as its visitors. A diverse and dynamic publication, Affair magazine gives readers the ultimate in stunning, creative photography and stimulating, relevant content, to ensure its unique market presence.
The wide range of businesses buying INTERScepter(TM) demonstrates the universal nature of the non-work related internet usage problem for all companies. If you have staff with access to the internet, you need INTERScepter(TM) now to keep them productive.
PROPALMS, INCORPORATED (OTC: PRPM)
"Up 34.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/PRPM.php
Propalms TSE, the complete Server-Based Management solution that extends Microsoft Terminal Services 2000/2003, offers features such as Application Publishing, Seamless Windows, Resource-based Load balancing, and Web-based management consoles.
PRPM News:
December 11 - Propalms, Inc. Retains Prestigious Law Firm Schiff Hardin LLP as General Counsel
Schiff Hardin Named 2008 'Best Lawyers in America'
Propalms, Inc. (OTC: PRPM) announced that the Company has signed an agreement with US-based law firm, Schiff Hardin LLP. The law firm was named 2008 "Best Lawyers in America." The team of lawyers at Schiff Hardin LLP will provide Propalms with counsel and assist with future mergers and acquisitions.
Schiff Hardin LLP is a general practice law firm with offices in seven cities. The firm has more than 400 attorneys in offices located in Atlanta, Boston, Chicago, Lake Forest, New York, San Francisco and Washington. Schiff Hardin's attorneys are admitted to practice law in more than 100 jurisdictions -- including 31 states, 72 U.S. courts, and six countries. The Schiff Hardin attorneys include former Securities and Exchange Commission directors and senior staff members, former general counsel at public companies, and experienced business lawyers from multiple disciplines and jurisdictions.
"We're very pleased to have retained Schiff Hardin. Schiff Hardin will serve as a major asset for us as we enter a new stage in our development. Whether it is Merger and Acquisition negotiations or general counsel it is integral for us to have the right team in place as we move to the next level. We're looking forward to accomplishing our Company goals while working with their renowned staff in 2008," stated Robert Zysblat, President of Propalms.
Propalms, Inc.'s annual shareholder meeting will be held on Friday, January 11, 2008, at 10:00 a.m. PST at the Luxor Hotel in Las Vegas, Nevada. Shareholders that would like to reserve a room at the hotel to attend the shareholder meeting should contact the Luxor Hotel at 888-777-0188 or 702-262-4444. The Luxor Hotel is located at 3900 Las Vegas Boulevard, South Las Vegas, Nevada, 89119. Propalms' shareholder meeting will be held in the Nile Chamber C. The Company filed its form 10SB to uplist to the Nasdaq Bulletin Board.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated four thousand dollars by a third party for AMZO email advertising services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
